NCT05107557View on ClinicalTrials.gov

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

PHASE4CompletedINTERVENTIONAL

Enrollment

520

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

December 5, 2021

Study Completion Date

July 14, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

Experimental Group

The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.

Trial Locations (2)

524005

Zhanjiang Center for Diseases Control and Prevention, Zhenjiang

529699

Yangchun City Center for Disease Control and Prevention, Yangchun

All Listed Sponsors

lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT05107557 - Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell) | Biotech Hunter | Biotech Hunter